Presentations & Events

Corporate Presentations

Upcoming Events

There are no upcoming events scheduled at this time.

Archived Events

Date Event Supporting Materials
Dec 05, 2024 at 8:45 AM EST
Citi 2024 Global Healthcare Conference
Listen to webcast
Nov 13, 2024 at 10:15 AM EST
UBS Global Healthcare Conference
Listen to webcast
Sep 18, 2024 at 3:40 PM EDT
2024 Cantor Fitzgerald Global Healthcare Conference
Listen to webcast
Sep 10, 2024 at 10:30 AM EDT
H.C. Wainwright 26th Annual Global Investment Conference
Listen to webcast
Jun 10, 2024 at 1:20 PM EDT
Goldman Sachs 45th Annual Global Healthcare Conference
Listen to webcast
May 15, 2024 at 12:20 PM EDT
BofA Securities Health Care Conference
Listen to webcast
Sep 27, 2023 at 1:50 PM EDT
Cantor Global Healthcare Conference
Listen to webcast

Scientific Posters

Zoliflodacin Phase 3 clinical trial topline data
 
Population Pharmacokinetic, PharmacokineticPharmacodynamic Attainment, and Clinical PharmacokineticPharmacodynamic Analyses for Sulbactam-Durlobactam to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex Infections

        IDWeek 2022
        Sujata Bhavnani, Pharm.D., M.S., FIDSA

Efficacy and Safety of Sulbactam-Durlobactam are Consistent Across Regions in the Global ATTACK Phase 3 Trial in the Treatment of Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex (CRABC) Infections

        IDWeek 2022
        Alita Miller, PhD, et al.

Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: Sulbactam-Durlobactam versus colistin therapy in patients with Acinetobacter baumanniicalcoaceticus complex infections

        IDWeek 2022
        David Altarac, MD.

Efficacy of Sulbactam-Durlobactam versus Colistin in Patients with XDR or PDR Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections

        IDWeek 2022
        Alita Miller, PhD.

Characterization of Colistin-Resistant Acinetobacter baumannii-calcoaceticus Complex (ABC) Isolates from a Recent, Global Phase 3 Trial (ATTACK)

        IDWeek 2022
        Samir H. Moussa, et al.

Safety Profile of Sulbactam-Durlobactam (SUL-DUR) Versus Colistin Therapy in Patients With Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections from the Global, Randomized, Active-Controlled Phase 3 Trial (ATTACK)

        IDWeek 2022
        D. Lewis, et al.

 
 
Innoviva

Minimum 15 minutes delayed. Source: LSEG